Japanese Red Cross Narita Hospital

Narita 286-8523

0 studies enrolling now · 2 studies all time

What they study most

Multiple Myeloma, Receptors, Fibroblast Growth Factor, Urothelial Cancer

Studies at this site

• A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide — Running, not enrolling
• A Study to Identify Participants With Urothelial Cancer and Fibroblast Growth Factor Receptor Gene Aberrations — Completed